Medical Pharmacology: Immunopharmacology (Immunosuppressant/Immunomodulator) Practice Questions
Siponimod (Mayzent)
Click on the correct answer.
Siponimod (Mayzent):
Relatively new oral drug targeting secondary progressive multiple sclerosis (SPMS).
Mechanism of action involves binding to sphingosine-1-phosphate receptors associated with lymphocytes and related cells.
Both
Neither
Siponimod (Mayzent) clinical use/uses:
Relapsing-remitting multiple sclerosis
Active secondary progressive multiple sclerosis
in adults.
Both
Neither
Relapsing-remitting multiple sclerosis (RRMS) is often associated with subsequent period of worsening neurological function, occurring independently of relapse. This phenomenon is described as secondary progressive MS (SPMS).
True
False
Relapsing-remitting MS (RRMS):
Likely driven by peripherally mediated inflammation
Likely associated with chronic central nervous system
(CNS) inflammation and neurodegeneration.
Both
Neither
Siponimod (Mayzent):
Orally active
Modulator at both sphingosine-1-phosphate Type 1 and 5 receptors
Both
Neither
Prior to first dose of siponimod administration:
CYP2C9 genotype assessment
ECG for the purpose of identifying preexisting cardiac conduction abnormalities.
Both
Neither
Siponimod and the heart:
Initial siponimod administration is likely to be associated with the reduction in heart rate.
A first-dose siponimod 6 hour monitoring period is appropriate for patients with existing sinus bradycardia (<55 BPM), 1st or 2nd degree AV block, myocardial infarction history, or heart failure.
